Loading news...
Overview of the Recent Transaction On December 31, 2025, Chuck Royce (Trades, Portfolio), a renowned figure in small-cap investing, made a notable transaction i
CLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025.
CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Drug Safety (MFDS).
CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.
CLEARWATER Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Apyx Medical Corporation ( APYX ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Charles Goodwin - President, CEO & Director Matthew Hill - CFO, Treasurer & Secretary Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC David Turkaly - Citizens JMP Securities, LLC, Research Division Sam Eiber - BTIG, LLC, Research Division Alex Fuhrman - Lucid Capital Markets, LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Apyx Medical Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 6, 2025.
CLEARWATER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that financial results for the third quarter of fiscal year 2025 will be released before markets open on Thursday, November 6th.
Apyx Medical Corporation - Special Call Company Participants Charles Goodwin - President, CEO & Director Conference Call Participants Paul Vanek Sam Eiber - BTIG, LLC, Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Alex Fuhrman - Lucid Capital Markets, LLC, Research Division David Turkaly - Citizens JMP Securities, LLC, Research Division Jeremy Feffer - Lifesci Advisors, LLC Presentation Operator Good afternoon, and welcome to the Apyx Medical Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Apyx Medical website following the conclusion of the event.
Apyx Medical Corporation (NASDAQ:APYX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Charles D. Goodwin - President, CEO & Director Matthew C.
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its quarter ended June 30, 2025.
CLEARWATER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion® and the AYON Body Contouring System™, today announced that management will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, in Boston, MA.
Highlighting Real Patient Journeys and Empowering Confidence Through Loose Skin Solutions and Body Contouring CLEARWATER, Fla. , May 30, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of the proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, is once again taking center stage—this time at Miami Swim Week.
The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System™ (“AYON”).
Apyx Medical Corporation (NASDAQ:APYX ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Jeremy Feffer – LifeSci Advisors Charlie Goodwin – Chief Executive Officer Matt Hill – Chief Financial Officer Conference Call Participants Matt Hewitt – Craig-Hallum Capital Group Sam Eiber – BTIG Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode.
Beloved Personality of "The Real Housewives of New Jersey" Provides a Real Take on the Problem of Loose Skin and the Power of Body Contouring Technology CLEARWATER, Fla. , May 1, 2025 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® today announces Dolores Catania as the Chief of Confidence for the brand's Renew You consumer marketing campaign which exemplifies the brand's ability to reshape bodies and lives.
Two studies report favorable clinical outcomes and safety data for Renuvion ® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking treatment for loose and lax skin CLEARWATER, Fla., April 29, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform marketed and sold as Renuvion®, today announced the publication of two peer-reviewed clinical studies evaluating the use of Renuvion during body contouring procedures that also included lipoabdominoplasty1.
CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th.
Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category.
Apyx Medical Corporation (NASDAQ:APYX ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Operator Greetings. Welcome to the Apyx Medical Fourth Quarter and Full Year 2024 Conference Call.
Apyx Medical (APYX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago.